Literature DB >> 15722570

HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract.

Donna E Hansel1, Ayman Rahman, Robb E Wilentz, Ie-ming Shih, Michael T McMaster, Charles J Yeo, Anirban Maitra.   

Abstract

HLA-G belongs to the nonclassical MHC class Ib group of molecules and has been implicated in mediating immune-responsiveness in various cancerous and non-cancerous cell types. We have examined HLA-G expression in a number of human gastrointestinal malignancies, including pancreatic ductal adenocarcinoma, ampullary cancer, biliary cancer, and colorectal cancer by immunolabeling analysis. We used indices of <5% (negative), 6-25%, 26-50%, 51-75%, and >75% (diffuse) to subclassify lesions based on percentage of positive cell labeling. Across all cancer subtypes, 52-79% of lesions demonstrated expression of HLA-G, with up to 33% of lesions demonstrating diffuse (>75%) expression. In addition, we utilized the neoplastic progression model of colorectal cancer to evaluate HLA-G protein expression in normal colon, tubulovillous adenomas, invasive cancer, and liver metastases arising from colorectal cancer. Focal HLA-G expression was detected in regions of normal colon adjacent to sites of adenomatous and cancerous lesions, as well as in all stages of cancer progression. Overall, the percentage of diffusely (>75%) labeled lesions appeared increased in preneoplastic and neoplastic conditions, as compared to normal colon. Specifically, tubulovillous adnenomas demonstrated pronounced diffuse labeling in 58% of lesions examined. No correlation with HLA-G expression and CD4+ or CD8+ T cells was identified. We propose that HLA-G expression is upregulated in a large percentage of gastrointestinal lesions and may serve to mediate immune-responsiveness in certain instances.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722570     DOI: 10.1385/ijgc:35:1:015

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  23 in total

Review 1.  HLA-G: a shield against inflammatory aggression.

Authors:  E D Carosella; P Moreau; S Aractingi; N Rouas-Freiss
Journal:  Trends Immunol       Date:  2001-10       Impact factor: 16.687

2.  A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity.

Authors:  R Marchal-Bras-Goncalves; N Rouas-Freiss; F Connan; J Choppin; J Dausset; E D Carosella; M Kirszenbaum; J Guillet
Journal:  Transplant Proc       Date:  2001-05       Impact factor: 1.066

3.  The HLA-G gene is expressed at a low mRNA level in different human cells and tissues.

Authors:  M Onno; T Guillaudeux; L Amiot; I Renard; B Drenou; B Hirel; M Girr; G Semana; P Le Bouteiller; R Fauchet
Journal:  Hum Immunol       Date:  1994-09       Impact factor: 2.850

4.  HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis.

Authors:  B Riteau; N Rouas-Freiss; C Menier; P Paul; J Dausset; E D Carosella
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

5.  Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells.

Authors:  P Paul; F A Cabestre; E C Ibrahim; S Lefebvre; I Khalil-Daher; G Vazeux; R M Quiles; F Bermond; J Dausset; E D Carosella
Journal:  Hum Immunol       Date:  2000-11       Impact factor: 2.850

6.  HLA-G protein expression is not induced during malignant transformation.

Authors:  C Pangault; L Amiot; S Caulet-Maugendre; F Brasseur; F Burtin; V Guilloux; B Drenou; R Fauchet; M Onno
Journal:  Tissue Antigens       Date:  1999-04

7.  HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance.

Authors:  P Paul; N Rouas-Freiss; I Khalil-Daher; P Moreau; B Riteau; F A Le Gal; M F Avril; J Dausset; J G Guillet; E D Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

8.  Analysis of HLA-E expression in human tumors.

Authors:  Rosario Marín; Francisco Ruiz-Cabello; Susana Pedrinaci; Rosa Méndez; Pilar Jiménez; Daniel E Geraghty; Federico Garrido
Journal:  Immunogenetics       Date:  2003-01-30       Impact factor: 2.846

9.  HLA-G is a potential tumor marker in malignant ascites.

Authors:  Gad Singer; Vera Rebmann; Yu-Chi Chen; Hsu-Tai Liu; Syed Z Ali; Jochen Reinsberg; Michael T McMaster; Kerstin Pfeiffer; Daniel W Chan; Eva Wardelmann; Hans Grosse-Wilde; Chih-Chien Cheng; Robert J Kurman; Ie-Ming Shih
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

Review 10.  HLA-G and MIC expression in tumors and their role in anti-tumor immunity.

Authors:  Barbara Seliger; Hinrich Abken; Soldano Ferrone
Journal:  Trends Immunol       Date:  2003-02       Impact factor: 16.687

View more
  13 in total

1.  HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer.

Authors:  Li Zhou; Zhe-Yu Niu; Zhi-Yong Liang; Wei-Xun Zhou; Lei You; Meng-Yi Wang; Lu-Tian Yao; Quan Liao; Yu-Pei Zhao
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 2.  Application of human leukocyte antigen-G expression in the diagnosis of human cancer.

Authors:  Ie-Ming Shih
Journal:  Hum Immunol       Date:  2007-02-20       Impact factor: 2.850

Review 3.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

Review 4.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 5.  Clinical and biological significance of HLA-G expression in ovarian cancer.

Authors:  Jim Jinn-Chyuan Sheu; Ie-Ming Shih
Journal:  Semin Cancer Biol       Date:  2007-07-03       Impact factor: 15.707

6.  Effects of fgf2 and oxygen in the bmp4-driven differentiation of trophoblast from human embryonic stem cells.

Authors:  Padmalaya Das; Toshihiko Ezashi; Laura C Schulz; Suzanne D Westfall; Kimberly A Livingston; R Michael Roberts
Journal:  Stem Cell Res       Date:  2007-10       Impact factor: 2.020

Review 7.  Non-classical transcriptional regulation of HLA-G: an update.

Authors:  Philippe Moreau; Sébastien Flajollet; Edgardo D Carosella
Journal:  J Cell Mol Med       Date:  2009-06-05       Impact factor: 5.310

8.  HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Authors:  Marica Garziera; Ettore Bidoli; Erika Cecchin; Enrico Mini; Stefania Nobili; Sara Lonardi; Angela Buonadonna; Domenico Errante; Nicoletta Pella; Mario D'Andrea; Francesco De Marchi; Antonino De Paoli; Chiara Zanusso; Elena De Mattia; Renato Tassi; Giuseppe Toffoli
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

9.  Expression of the Classical and Nonclassical HLA Molecules in Breast Cancer.

Authors:  Gisela Bevilacqua Rolfsen Ferreira da Silva; Tarsia Giabardo Alves Silva; Roberta Aparecida Duarte; Nicolino Lia Neto; Hélio Humberto Angotti Carrara; Eduardo Antônio Donadi; Maria Alice Guimarães Gonçalves; Edson Garcia Soares; Christiane Pienna Soares
Journal:  Int J Breast Cancer       Date:  2013-12-02

10.  Human Leukocyte antigen-G (HLA-G) and gastrointestinal malignancy.

Authors:  Ehsan Nazemalhosseini-Mojarad; Peter J K Kuppen; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.